Cargando…

Corrigendum: The role of 18F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy

Detalles Bibliográficos
Autores principales:	Wang, Guanyun, Zhang, Wenwen, Luan, Xiaohui, Wang, Zhanbo, Liu, Jiajin, Xu, Xiaodan, Zhang, Jinming, Xu, Baixuan, Lu, Shichun, Wang, Ruimin, Ma, Guangyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241066/ https://www.ncbi.nlm.nih.gov/pubmed/37283748 http://dx.doi.org/10.3389/fimmu.2023.1219757

Ejemplares similares

The role of (18)F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy
por: Wang, Guanyun, et al.
Publicado: (2023)

Pretreatment Metabolic Parameters Measured by (18)F-FDG PET to Predict the Pathological Treatment Response of HCC Patients Treated With PD-1 Inhibitors and Lenvatinib as a Conversion Therapy in BCLC Stage C
por: Wang, Guanyun, et al.
Publicado: (2022)

Multiparameter diagnostic model based on (18)F-FDG PET metabolic parameters and clinical variables can differentiate nonmetastatic gallbladder cancer and cholecystitis
por: Li, Can, et al.
Publicado: (2023)

Can (18)F-PSMA-7Q PET/CT replace prostate biopsy for the diagnosis of prostate cancer?—A single-center retrospective study
por: Liu, Yachao, et al.
Publicado: (2023)

Multiparameter diagnostic model based on (18)F-FDG positron emission tomography and serological examination for differentiating focal autoimmune pancreatitis from pancreatic ductal adenocarcinoma
por: Wang, Guanyun, et al.
Publicado: (2023)

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial
por: Zhang, Wenwen, et al.
Publicado: (2023)

Diagnostic Value of (11)C-PIB PET/MR in Cardiac Amyloidosis
por: Bi, Xiao, et al.
Publicado: (2022)

Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?
por: Luo, Laihui, et al.
Publicado: (2022)

Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study
por: Fu, Zhigang, et al.
Publicado: (2021)

Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study
por: Wang, Wei‐Jun, et al.
Publicado: (2023)

Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports
por: Tomonari, Tetsu, et al.
Publicado: (2020)

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
por: Kobayashi, Masahiro, et al.
Publicado: (2019)

A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
por: Lee, Jaejun, et al.
Publicado: (2020)

Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Multiparameter diagnostic model based on (18)F-FDG PET and clinical characteristics can differentiate thymic epithelial tumors from thymic lymphomas
por: Wang, Guanyun, et al.
Publicado: (2022)

Multiparameter Analysis Using (18)F-FDG PET/CT in the Differential Diagnosis of Pancreatic Cystic Neoplasms
por: Wang, Guanyun, et al.
Publicado: (2021)

A Preclinical Study of an (125)I-Labeled PSMA Ligand for Prostate-Cancer Puncture
por: Luan, Xiaohui, et al.
Publicado: (2022)

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
por: Zhao, Shu, et al.
Publicado: (2022)

Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study
por: Wang, Yajing, et al.
Publicado: (2023)

Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study
por: Qu, Wei-Feng, et al.
Publicado: (2022)

Improving MR sequence of 18F-FDG PET/MR for diagnosing and staging gastric Cancer: a comparison study to (18)F-FDG PET/CT
por: Zheng, Dong, et al.
Publicado: (2020)

Anti-PD-1 antibodies plus lenvatinib in patients with unresectable hepatocellular carcinoma who progressed on lenvatinib: a retrospective cohort study of real-world patients
por: Zou, Jixue, et al.
Publicado: (2022)

A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma
por: Gan, Leijuan, et al.
Publicado: (2023)

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
por: Personeni, Nicola, et al.
Publicado: (2019)

Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2021)

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors
por: Li, Xingzhi, et al.
Publicado: (2023)

Integrin subunit beta 8 contributes to lenvatinib resistance in HCC
por: Hou, Wei, et al.
Publicado: (2022)

Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy
por: Guo, De-Zhen, et al.
Publicado: (2023)

Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients
por: Zhang, Wenwen, et al.
Publicado: (2021)

Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas
por: Hassan Nelson, Lauren, et al.
Publicado: (2022)

Impact of combining Lenvatinib with Transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Long, Jianwu, et al.
Publicado: (2023)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
por: Chen, Yen-Yang, et al.
Publicado: (2020)

(18)F-Florbetaben Amyloid PET Imaging: A Chinese Study in Cognitive Normal Controls, Mild Cognitive Impairment, and Alzheimer’s Disease Patients
por: Chang, Yan, et al.
Publicado: (2020)

Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report
por: Zhang, Ze, et al.
Publicado: (2021)

Machine Learning to Predict the Response to Lenvatinib Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma
por: Ma, Jun, et al.
Publicado: (2023)

Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China
por: Zhu, Yun, et al.
Publicado: (2021)

Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
por: Sun, Liwei, et al.
Publicado: (2022)

Impact of Grip Strength in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib
por: Endo, Kei, et al.
Publicado: (2020)

A Case of Unresectable Combined Hepatocellular-Cholangiocarcinoma Successfully Treated with Lenvatinib
por: Osuga, Takahiro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pahcrdfiuge6kiv2g1dlscgsb2